Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial (Businesswire) - Sep 5, 2024 - "Aurinia Pharmaceuticals...announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025."
P1 data • Trial status • Lupus
|